MART-1-specific T-cell receptor (MART-1 TCR) (MART-1 TCR)

The MART-1-specific T-cell receptor (TCR) is a specialized heterodimeric protein complex found on the surface of CD8+ T cells that recognizes the MART-1 (Melan-A) antigen presented by HLA class I molecules, specifically HLA-A*02:01 (Source: PubMed 16946036). MART-1 is a melanocyte differentiation antigen that is highly expressed in the majority of human melanomas, making it a significant target for cancer immunotherapy (Source: UniProt Q16655). In therapeutic applications, high-affinity TCR clonotypes, such as the DMF5 clone, are identified and used to genetically engineer a patient's own T cells to create TCR-T cell therapies (Source: PubMed 19033483). These engineered T cells are designed to specifically bind to the MART-1 peptide-HLA complex on the surface of melanoma cells, triggering T-cell activation and the subsequent release of cytotoxic granules to induce tumor cell death. However, because MART-1 is also expressed in healthy melanocytes, these therapies can cause "on-target, off-tumor" toxicities, leading to the destruction of normal cells in the skin, inner ear, and uvea of the eye (Source: PubMed 21437605). Consequently, clinical management of MART-1 TCR-T therapy requires careful monitoring for autoimmune-like side effects such as vitiligo, hearing loss, and uveitis. Despite these challenges, the MART-1 TCR remains a critical tool in the development of adoptive cell transfer strategies for solid tumors.

Other names

Melan-A-specific T-cell receptorMART-1/HLA-A*02:01-specific TCRMelanoma-associated antigen recognized by T cells 1-specific TCRMART-1-specific TCR

Adoptive T-cell therapy utilizing genetically engineered T cells expressing a specific TCR that recognizes MART-1 peptide-HLA-A*02:01 complexes to induce tumor cell lysis (Source: PubMed 16946036).